The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Verb Technology Company, Inc. – VERB

LOS ANGELES, Nov. 11, 2020 (GLOBE NEWSWIRE) — The Rosen Law Firm, P.A. announces that the United States District Court for the Central District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of Verb Technology Corporation, Inc. (NASDAQ: VERB):

SUMMARY NOTICE OF PENDENCY AND


PROPOSED CLASS ACTION SETTLEMENT

TO:        ALL PERSONS WHO PURCHASED VERB TECHNOLOGY COMPANY, INC. (“VERB”) COMMON STOCK FROM JANUARY 3, 2018 THROUGH MAY 2, 2018, INCLUSIVE.

YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the Central District of California, that a hearing will be held on February 18, 2021, at 8:30 a.m. before the Honorable George H. Wu, United States District Judge of the United States District Court for the Central District of California, First Street Federal Courthouse, 350 W. First Street, Courtroom 9D, 9th Floor, Los Angeles, CA 90012, or by telephonic or videoconference means as directed by the Court, for the purpose of determining:

(1) whether the proposed Settlement of the claims in the above-captioned Action for consideration including the sum of $640,000 should be approved by the Court as fair, reasonable, and adequate;

(2) whether the proposed plan to distribute the Settlement proceeds is fair, reasonable, and adequate;

(3) whether the application of Lead Counsel for an award of attorneys’ fees of up to 25% of the Settlement Amount, reimbursement of expenses of not more than $25,000, and an award of no more than $1,000 to Plaintiffs, should be approved; and

(4) whether this Action should be dismissed with prejudice as set forth in the Stipulation of Settlement dated September 17, 2020 (“Stipulation”).

If you purchased Verb common stock during the period from January 3, 2018 through May 2, 2018, inclusive (“Settlement Class Period”), your rights may be affected by this Settlement, including the release and extinguishment of claims you may possess relating to your ownership interest in Verb common stock. If you have not received a postcard providing instructions for receiving a detailed Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and a copy of the Proof of Claim and Release Form (“Proof of Claim”), you may obtain copies by writing to or calling the Claims Administrator: Verb Technology Company, Inc. Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (Tel) (866) 274-4004; (Fax) (610) 565-7985; [email protected], or going to the website, www.strategicclaims.net. If you are a member of the Settlement Class, to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim to the Claims Administrator, postmarked no later than February 4, 2021, establishing that you are entitled to recovery. Unless you submit a written exclusion request, you will be bound by any judgment rendered in the Action whether or not you make a claim.

If you desire to be excluded from the Settlement Class, you must submit a request for exclusion in the manner and form explained in the Notice to the Claims Administrator so that it is received no later than January 28, 2021. All members of the Settlement Class who have not requested exclusion from the Settlement Class will be bound by any judgment entered in the Action.

Any objection to the Settlement, Plan of Allocation, or Lead Counsel’s request for an award of attorneys’ fees and reimbursement of expenses and award to Plaintiffs must be in the manner and form explained in the Notice and received no later than January 28, 2021, by each of the following:

Clerk of the Court
United States District Court
Central District of California
First Street Federal Courthouse
350 W. First Street, Suite 4311
Los Angeles, CA 90012

LEAD COUNSEL:

Jacob A. Goldberg
The Rosen Law Firm, P.A.
101 Greenwood Avenue, Suite 440
Jenkintown, PA 19046

COUNSEL FOR DEFENDANTS

Steven M. Schatz
Catherine E. Moreno
WILSON SONSINI GOODRICH & ROSATI, P.C.
650 Page Mill Road
Palo Alto, CA 94304

If you have any questions about the Settlement, you may call or write to Lead Counsel:

Jacob A. Goldberg
The Rosen Law Firm, P.A.
101 Greenwood Avenue, Suite 440
Jenkintown, PA 19046
Tel.: 215-600-2817

PLEASE DO NOT CONTACT THE COURT OR THE CLERK’S OFFICE REGARDING THIS NOTICE.

Dated: October 28, 2020                                                         BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fluidigm Corporation – FLDM

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Fluidigm Corporation (“Fluidigm” or the “Company”) (NASDAQ: FLDM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Fluidigm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On August 1, 2019, Fluidigm reported second quarter 2019 revenues of $28.2 million, well below analysts’ expectations of $32 million, citing weakness in the Company’s microfluidics segment.  On this news, Fluidigm’s stock price fell $4.10 per share, or 34%, to close at $8.05 per share on August 2, 2019. 

Then, on November 5, 2019, Fluidigm reported that its third quarter 2019 revenue had declined 8.5% year-over-year.  On this news, Fluidigm’s stock price fell $2.60 per share, or 51%, to close at $2.51 per share on November 6, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Celebrate Thanksgiving with Dickey’s Barbecue Pit’s Holiday Feasts

World’s largest barbecue concept is offering heat-and-eat and new ready-to-eat holiday options, available for pickup and delivery

Dallas, TX, Nov. 11, 2020 (GLOBE NEWSWIRE) — From family gatherings to socially distanced celebrations, Dickey’s Barbecue Pit has everything you need to enjoy a stress-free Thanksgiving!

There is a lot to be grateful for this holiday season including the convenience of Dickey’s new holiday catering options. This year, Dickey’s fans can order individualized holiday box lunches containing slow-smoked carved turkey sandwiches, sides of cornbread dressing, bags of chips and cookies along with a to-go sauce of the guests’ choice. The family-owned restaurant brand is also offering a deluxe version of its new holiday box lunch option that includes an additional fan-favorite holiday side of southern-style green beans.

For mid-size gatherings of eight to 12, Dickey’s is also offering a new ready-to-eat Holiday Big Yellow Box which comes with sliced turkey breast, cornbread dressing, gravy, baked potato casserole, green beans with bacon and a dozen buttery rolls.

Available for pickup and delivery throughout the holiday season from participating Dickey’s locations,  guests can enjoy these heat-and-eat options:

  • The Complete Feast – Choose from smoked turkey, prime rib, Cajun-fried turkey or spiral ham along with cornbread dressing, gravy, baked potato casserole, green beans with bacon and a dozen buttery rolls.
  • The Dinner Feast – Choose from smoked turkey, prime rib, Cajun-fried turkey or spiral ham along with cornbread dressing, gravy and a dozen buttery rolls.
  • À La Carte Menu – Order any of Dickey’s slow smoked holiday meats of savory sides individually.

“This year is anything but traditional and we want to do what we can to help make sure that all of our guests enjoy Thanksgiving without the added stress of having to cook,” said Laura Rea Dickey, CEO of Dickey’s Barbecue Restaurants, Inc. “Our holiday feasts have always been a big hit and this year, we’ve debuted the Holiday Big Yellow Box, which is a delicious ready-to-eat option. Whether you’re looking for delicious, high-quality sides, slow smoked meats or dessert, Dickey’s is here to help!”

To place an order for a holiday feast from Dickey’s, visit dickeys.com/quote/order-menu.

Dickey’s can also tailer a catering menu for any event or occasion. Get a free quote at Dickeys.com or call a Catering Expert at 866-BARBECUE for details on holiday buffets for large events or the Holiday Big Yellow Box lunches for smaller events.
 
To learn more, follow Dickey’s Franchise on Facebook, Instagram and Twitter. Download the Dickey’s Barbecue Pit app from the Apple App Store or Google Play.

About Dickey’s Barbecue Restaurants, Inc.

Dickey’s Barbecue Restaurants, Inc., the world’s largest barbecue concept, was founded in 1941 by Travis Dickey. For the past 79 years, Dickey’s Barbecue Pit has served millions of guests Legit. Texas. Barbecue.™ At Dickey’s, all our barbecued meats are smoked onsite in a hickory wood burning pit. Dickey’s proudly believes there’s no shortcut to true barbecue and it’s why they never say bbq. The Dallas-based, family-run barbecue franchise offers several slow-smoked meats and wholesome sides with ‘No B.S. (Bad Stuff)’ included. The fast-casual concept has expanded worldwide with two international locations in the UAE and operates over 500 locations in 44 states. In 2016, Dickey’s won first place on Fast Casual’s “Top 100 Movers and Shakers” list and was named a Top 500 Franchise by Entrepreneur in 2018. Dickey’s Barbecue Pit has also been recognized by Fox News, Franchise Times, The Wall Street Journal, QSR Magazine, Forbes Magazine and Nation’s Restaurant News. For more information, visit www.dickeys.com

 

# # #

Attachment

Greer Martin
Dickey's Barbecue Restaurants, Inc.
9729713898
[email protected]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pintec Technology Holdings Limited – PT

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Pintec Technology Holdings Limited (“Pintec” or the “Company”) (NASDAQ: PT).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Pintec and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

In October 2018, Pintec completed its initial public offering (“IPO”), selling more than 3.7 million American Depositary Shares (“ADSs”) priced at $11.88 per share.  On July 30, 2019, after the market closed, the Company filed its fiscal 2018 annual report, in which it restated previously disclosed financial results.  Among other things, the Company reported net income of $315,000 for fiscal 2018, compared to its prior disclosure of $1.068 million net income.  

Pintec also disclosed that there were material weaknesses in its internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs.  On this news, Pintec’s ADS price fell $0.53 per share, or more than 13%, over the following trading sessions, to close at $3.40 per share on August 5, 2019. 

Then, on June 15, 2020, Pintec disclosed that it could not timely file its fiscal 2019 annual report and that it anticipated reporting a significant change in results of operations.  Specifically, the Company disclosed that it “erroneously recorded revenue earned from certain technical service fee on a net basis” for fiscal 2017 and 2018.  Moreover, Pintec “announced a net loss of RMB906.5 million in the full year of 2019 due to RMB890.7 million of provision for credit loss in amounts due from a related party, Jimu Group, and RMB200 million of impairment in prepayment for long-term investment.”  Since the IPO, Pintec’s ADSs have closed as low as $0.47 per share, representing a decline of more than 96% from the IPO price.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

Pampa Energía announces results for the nine-month period and quarter ended on September 30, 2020

PR Newswire

BUENOS AIRES, Nov. 11, 2020 /PRNewswire/ — Pampa Energía S.A. (NYSE: PAM; Buenos Aires Stock Exchange: PAMP), the largest independent energy integrated company in Argentina, with active participation in the country’s electricity and gas value chain, announces the results for the nine-month period and quarter ended on September 30, 2020.

As from January 1, 2019, the Company adopted US$ as functional currency for the reporting of its financial information. The presentation of this information in AR$ is converted at transactional nominal exchange rate (‘FX’).

However, Edenor (electricity distribution), OldelVal (oil and gas), Transener, TGS and Refinor (holding and others) continue recording their operations in local currency. Thus, the 2020 figures are adjusted by inflation as of September 30, 2020 (9M20: 10.0% and Q3 20: 3.7%), translated to US$ at closing FX of 76.18. Moreover, the 2019 figures are adjusted by inflation as of September 30, 2019 (9M19: 15.9% and Q3 19: 5.9%), translated to US$ at closing FX of 57.59[1].


Main highlights from the 9M20 results

Consolidated net revenues of US$1,651 million[2], 23% lower than the US$2,137 million recorded in 9M19, mainly due to tariff freeze in the regulated businesses, lower gas sales for own power generation, fall on prices and volumes of hydrocarbons and petrochemicals products, and lower remuneration for spot energy, partially offset by the commissioning of new power generation units priced under PPA.

  • Power Generation of 12,069 GWh from 15 power plants[3]
  • Electricity sales of 15,427 GWh to 3.1 million end-users
  • Production of 45.5 thousand boe per day of hydrocarbons
  • Sales of 230 thousand tons of petrochemical products

Consolidated adjusted EBITDA[4] of US$583 million, 20% lower than the US$731 million in 9M19, due to decreases of 55% in electricity distribution and 53% in oil and gas, partially offset by increases of 7% in petrochemicals, 4% in power generation and 1% in holding and others.

Consolidated gain attributable to the owners of the Company of US$96 million, 86% lower than the US$683 million profit achieved in 9M19, mainly due to the one-off non-cash profit from the settlement of Edenor’s regulatory liabilities in 9M19, in addition to lower operating margin, lesser RECPAM recorded due to the lower passive net monetary position allocated to the electricity distribution segment, plus impairment of accrued assets and an income tax charge in 9M20.


Main highlights from the Q3 20 results[5]

Consolidated net revenues of US$592 million, 2% higher than the US$581 million recorded in Q3 19, mainly due to the commissioning of the new combined cycle gas turbine Genelba Plus and the strong devaluation in Q3 19 which implied a dilution of sales in Edenor, partially offset by reductions on fuel sales for own thermal power dispatch, lower prices and volumes of hydrocarbons sold, and lower prices and dispatch at spot energy.

  • Power Generation of 4,000 GWh from 15 power plants
  • Electricity sales of 5,434 GWh to 3.1 million end-users
  • Production of 46.8 thousand boe per day of hydrocarbons
  • Sales of 90 thousand tons of petrochemical products

Consolidated adjusted EBITDA of US$234 million, 3% lower than the US$242 million in Q3 19, due to decreases of 38% in electricity distribution and 31% in oil and gas, partially offset by increases of US$19 million in holding and others, US$4 million in petrochemicals and US$1 million in power generation.

Consolidated gain attributable to the owners of the Company of US$78 million, 33% lower than the US$116 million gain recorded in Q3 19, mainly explained by the financial effect from the Agreement for the Regularization and Settlement of Receivables with the WEM executed in Q3 19 and lower operating margin in oil and gas, partially offset by higher profit in our equity income.

 



Consolidated Balance Sheet


(As of September 30, 2020 and December 31, 2019, in millions)

Figures in million


As of 9.30.2020


As of 12.31.2019

AR$

US$ FX 76.18

AR$

US$ FX 59.89


ASSETS

Property, plant and equipment

256,828

3,371

210,056

3,507

Intangible assets

10,494

138

9,068

151

Right-of-use assets

1,092

14

930

16

Deferred tax assets

8,142

107

1,702

28

Investments in joint ventures and associates

41,801

549

30,638

512

Financial assets at amortized cost

7,624

100

1,048

17

Financial assets at fair value through profit and loss

853

11

671

11

Other assets

53

1

45

1

Trade and other receivables

4,497

59

4,711

79


Total non-current assets


331,384


4,350


258,869


4,322

Inventories

10,244

134

9,175

153

Financial assets at amortized cost

2,759

36

3,224

54

Financial assets at fair value through profit and loss

11,170

147

21,867

365

Derivative financial instruments

214

4

Trade and other receivables

42,188

554

33,583

561

Cash and cash equivalents

24,625

323

13,496

225


Total current assets


90,986


1,194


81,559


1,362


Total assets


422,370


5,544


340,428


5,684


EQUITY


Total equity


178,771


2,347


144,262


2,409


LIABILITIES

Investments in joint ventures and associates

184

2

265

4

Provisions

10,767

141

8,703

145

Income tax liabilities

8,776

115

590

10

Deferred revenue

1,487

20

270

5

Taxes payables

128

2

263

4

Deferred tax liabilities

26,751

351

22,068

368

Defined benefit plans

2,395

31

1,606

27

Salaries and social security payable 

340

4

241

4

Borrowings

110,582

1,452

105,629

1,764

Trade and other payables

7,471

98

5,419

90


Total non-current liabilities


168,881


2,217


145,054


2,422

Provisions

1,639

22

1,206

20

Deferred revenue

32

0

5

0

Income tax liabilities

1,405

18

3,154

53

Taxes payables

4,595

60

4,316

72

Defined benefit plans

243

3

230

4

Salaries and social security payable 

3,714

49

3,834

64

Derivative financial instruments

22

0

204

3

Borrowings

20,612

271

10,974

183

Trade and other payables

42,456

557

27,189

454


Total current liabilities


74,718


981


51,112


853


Total liabilities


243,599


3,198


196,166


3,275


Total liabilities and equity


422,370


5,544


340,428


5,684

 

 



Consolidated Income Statement


(For the nine-month period and quarter ended on September 30, 2020 and 2019, in millions)


Nine-month period


Third quarter

Figures in million


2020


2019


2020


2019

AR$

US$

AR$

US$

AR$

US$

AR$

US$

Sales revenue

119,493

1,651

110,198

2,137

47,705

592

44,606

581

Cost of sales

(87,675)

(1,208)

(77,931)

(1,484)

(33,549)

(410)

(31,061)

(372)


Gross profit


31,818


443


32,267


653


14,156


182


13,545


209

Selling expenses

(9,556)

(129)

(5,785)

(104)

(4,062)

(50)

(2,141)

(18)

Administrative expenses

(7,950)

(112)

(5,757)

(118)

(2,885)

(36)

(2,132)

(32)

Exploration expenses

(21)

(155)

(4)

(12)

(84)

(2)

Other operating income

4,163

58

3,932

85

1,706

21

1,398

18

Other operating expenses

(3,059)

(43)

(3,189)

(64)

(977)

(12)

(1,232)

(17)

Results for part. in joint businesses and associates

4,809

66

3,429

62

1,652

20

501

(7)

Impairment of PPE and inventory

(4,316)

(67)

Agreement from regularization of liabilities

15,296

266

2,230

(42)


Operating income


15,888


216


40,038


776


9,578


125


12,085


109

RECPAM

5,997

79

8,514

148

2,738

33

2,689

11

Financial income

545

8

925

22

238

4

164

4

Financial costs

(14,019)

(198)

(10,669)

(219)

(5,728)

(74)

(3,518)

(49)

Other financial results

1,764

27

1,966

56

1,331

18

1,428

50



Financial results, net



(5,713)



(84)



736



7



(1,421)



(19)



763



16


Profit before tax


10,175


132


40,774


783


8,157


106


12,848


125

Income tax

(3,944)

(49)

(2,828)

7

(1,987)

(28)

(3,987)

(29)


Net income (loss) for the period


6,231


83


37,946


790


6,170


78


8,861


96



Attributable to the owners of the Company



7,156



96



31,863



683



6,161



78



8,159



116



Attributable to the non-controlling interests



(925)



(13)



6,083



107



9







702



(20)


Net income per share attributable to the shareholders


4.56


0.06


17.43


0.37


4.08


0.05


4.59


0.07


Net income per ADR attributable to the shareholders


113.90


1.53


435.76


9.34


101.99


1.29


114.75


1.63

 

For the full version of the Earnings Report, please visit Pampa’s Investor Relations website: ri.pampaenergia.com/en.


Information about the videoconference

There will be a videoconference to discuss Pampa’s Q3 20 results on Thursday November 12, 2020 at 10:00 a.m. Eastern Standard Time/12:00 a.m. Buenos Aires Time.

The hosts will be Gustavo Mariani, CEO, Gabriel Cohen, CFO and Lida Wang, investor relations and sustainability officer at Pampa.

For those interested in participating, please register at bit.ly/Pampa3Q20VideoCall. The videoconference call will also be simultaneously webcasted at Pampa’s website ri.pampaenergia.com/en.

You may find additional information on the Company at:

For more information, contact:

Gustavo Mariani

CEO

Gabriel Cohen

CFO

Lida Wang

Investor relations and sustainability officer

The Pampa Energía Building, Maipú 1 (C1084ABA) City of Buenos Aires, Argentina
Tel: +54 (11) 4344-6000
[email protected] 
ri.pampaenergia.com/en

[1] For further information, see section 3 of Pampa’s financial statements (‘FS’).

[2] Under International Financial Reporting Standards (‘IFRS’), sales at our ownership from the affiliates Greenwind, OldelVal, Refinor, CTBSA, Transener and TGS are not consolidated in Pampa, being its equity income shown as ‘Results for participation in joint businesses and associates’ (9M20: US$305 million and Q3 20: US$97 million).

[3] Includes 100% of Ensenada Barragán Thermal Power Plant (‘CTEB’) and Mario Cebreiro Wind Farm (‘PEMC’), assets operated by Pampa but co-controlled by Pampa, with 50% of equity stake.

[4] Consolidated adjusted EBITDA represents the results before financial results, income tax, depreciations and amortizations, extraordinary and non-cash income and expense, equity income and other adjustments from the IFRS implementation, and includes affiliates’ EBITDA at our ownership. For more information, see section 3 of the Earnings Release.

[5] The financial information presented in this document for Q3 20 and Q3 19 quarters are based on FS prepared according to IFRS in force in Argentina, corresponding to the nine-month period of 2020 and 2019, and the quarters ended June 30, 2020 and 2019, respectively.

 

Cision View original content:http://www.prnewswire.com/news-releases/pampa-energia-announces-results-for-the-nine-month-period-and-quarter-ended-on-september-30-2020-301171359.html

SOURCE Pampa Energia S.A.

Taseko Announces US$23 Million Bought Deal and up to US$2 Million Concurrent Private Placement

PR Newswire

VANCOUVER, BC, Nov. 11, 2020 /PRNewswire/ – Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Taseko” or the “Company“) announces that the Company has entered into an agreement dated November 11, 2020 with Cantor Fitzgerald Canada Corporation (the “Lead Underwriter“), as lead underwriter and sole book-runner on behalf of itself and a syndicate of underwriters (collectively, the “Underwriters“), to purchase, on a bought deal basis, 27,750,000 common shares of the Company (the “Offered Shares“) at the price of US$0.83 per Offered Share (the “Issue Price“) for aggregate gross proceeds of approximately US$23.0 million (the “Offering“).

In addition, Taseko has agreed to grant to the Underwriters an over-allotment option exercisable, in whole or in part, in the sole discretion of the Underwriters, to purchase up to an additional 4,162,500 common shares (representing 15% of the total number of common shares comprised in the Offering) at the Issue Price for a period of up to 30 days after the closing of the Offering for potential gross proceeds of up to approximately US$3.5 million. The Company has agreed to pay the Underwriters a cash commission equal to 6.0% of the gross proceeds of the Offering, including proceeds received from the exercise of the over-allotment option.

Proceeds of the Offering are anticipated to be used to fund ongoing operating, engineering and project costs in connection with the advancement of the Company’s Florence Copper Project and for general corporate purposes and working capital. 

The Offering is expected to close on or about November 17, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Toronto Stock Exchange (“TSX“) the NYSE American stock exchange (“NYSE“), the London Stock Exchange (“LSE“) and the United Kingdom Financial Conduct Authority.  The Company anticipates that the Offered Shares will, in due course, be listed for trading on each of the TSX, NYSE and the LSE.

The Offering will be made by way of a prospectus supplement (the “Prospectus Supplement“) to the Company’s existing Canadian base shelf prospectus (the “Base Shelf Prospectus“) and related U.S. registration statement on Form F-10 (SEC File No. 333-237948) (the “Registration Statement“).  The U.S. form of Base Shelf Prospectus is included in the Registration Statement.  The Prospectus Supplement has been filed with the securities commissions in each of the provinces of Canada (other than Québec) and the United States Securities and Exchange Commission (the “SEC“). The Canadian Prospectus Supplement (together with the related Canadian Base Shelf Prospectus) will be available on SEDAR at www.sedar.com. The United States Prospectus Supplement (together with U.S. Base Shelf Prospectus and the Registration Statement) will be available on the SEC’s website at www.sec.gov.  Alternatively, the Prospectus Supplement may be obtained, when available, upon request by contacting the Company at 15th Floor, 1040 West Georgia Street, Vancouver, British Columbia V6E 4H1, Attention: Corporate Secretary or by contacting Cantor Fitzgerald Canada Corporation in Canada, Attention: Equity Capital Markets, 181 University Avenue, Suite 1500, Toronto, Ontario M5H 3M7, email: [email protected] or Cantor Fitzgerald & Co. in the United States, Attention: Equity Capital Markets, 499 Park Avenue, 6th Floor, New York, New York, 10022, email: [email protected].

Acting as the stabilizing manager in connection with the Offering, the Lead Underwriter or any of its agents, may (but will be under no obligation to), to the extent permitted by applicable law, over-allot common shares or effect other transactions with a view to supporting the market price of the common shares at a higher level than that which might otherwise prevail in the open market. The Lead Underwriter (or any of its agents) is not required to enter into such transactions and such transactions may be effected on any securities market, over-the-counter market, stock exchange or otherwise and may be undertaken at any time during the period commencing on the closing date of the Offering and ending no later than the 30th calendar day after the closing date of the Offering.  However, there will be no obligation on the Lead Underwriter or any of its agents to effect stabilizing transactions and there is no assurance that stabilizing transactions will be undertaken.  Such stabilization, if commenced, may be discontinued at any time without prior notice.  In no event will measures be taken to stabilize the market price of the common shares above the Issue Price. The Lead Underwriter (or any of its agents) may, for stabilization purposes, over-allot common shares up to a maximum of 15 per cent. Except as required by law or regulation, neither the Underwriters nor any of their agents intend to disclose the extent of any over-allotments made and/or stabilization transactions conducted in relation to the Offering.

In addition to the Offering, Taseko is proposing to undertake a non-brokered private placement of up to 2,409,639 common shares of the Company at the Issue Price for gross proceeds to the Company of up to US$2.0 million (the “Concurrent Private Placement“).  No commission or finder’s fee is payable to the Underwriters in connection with the Concurrent Private Placement. Common shares issued pursuant to the Concurrent Private Placement will be subject to applicable resale restrictions, including a four month hold period under Canadian securities legislation. Closing of the Concurrent Private Placement is subject to the approval of the TSX and the NYSE. Closing of the Offering is not conditional upon the closing of the Concurrent Private Placement and closing of the Concurrent Private Placement is not conditional on the closing of the Offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon by the accuracy or adequacy of the Prospectus Supplement, the Base Shelf Prospectus or the Registration Statement.

This communication has been issued by, and is the sole responsibility, of the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Lead Underwriter or by any of its affiliates, directors, officers, employees, advisers or agents as to or in relation to, the accuracy or completeness of this communication or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed. The Lead Underwriter has not authorized the contents of, or any part of, this communication.

Russell Hallbauer

Chief Executive Officer and Director

CAUTION REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively referred to as “forward-looking information”). The use of any of the words “expect”, “plan”, “update” and similar expressions are intended to identify forward-looking information or statements. These statements include expectations about the likelihood of completion of the Offering and the Concurrent Private Placement, the amount of funds to be raised, the use of proceeds of the Offering and the Concurrent Private Placement, the anticipated closing date of the Offering and the Concurrent Private Placement, the ability of the Company to secure the required stock exchange acceptances for the Offering and the Concurrent Private Placement, the undertaking of any stabilization transactions in connection with the Offering, and the advancement of the development of the Company’s Florence Copper Project. Though the Company believes the expectations expressed in its forward-looking statements are based on reasonable assumptions, such statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements.  For further information on Taseko and the assumptions and risks related to Taseko’s business and forward looking statements, investors should review the Company’s annual information form, annual MD&A and audited financial statements filed by the Company under Canadian securities laws at www.sedar.com and included in the Company’s annual report on Form 40-F filed with the United States Securities and Exchange Commission at www.sec.gov, together with the Prospectus Supplement and other continuous disclosure filings made by the Company that have been filed at www.sedar.com and www.sec.gov and incorporated by reference into the Prospectus Supplement.

For readers in the European Economic Area and the United Kingdom

In any EEA Member State and the United Kingdom (each, a “Relevant State“), this communication is only addressed to and directed at qualified investors in that Relevant State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.

For readers in the United Kingdom

This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act 2000 as amended) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom; (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) (Investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order“); (iii) certain high net worth companies and persons who fall within Article 49(2)(a) to (d) (High net worth companies, unincorporated associations etc.) of the Order; and/or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as “relevant persons”). The Offered Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Offered Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

Cision View original content:http://www.prnewswire.com/news-releases/taseko-announces-us23-million-bought-deal-and-up-to-us2-million-concurrent-private-placement-301171358.html

SOURCE Taseko Mines Limited

IIROC Trade Resumption – ENBI

Canada NewsWire

VANCOUVER, BC, Nov. 11, 2020 /CNW/ – Trading resumes in:

Company: Entheon Biomedical Corp. (Formerly ‘MPV Explorations Inc.’)

CSE Symbol: ENBI (Formerly ‘MPV’)

Resumption (ET): 9:30 AM 11/12/2020

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NextCure, Inc. – NXTC

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of NextCure (“NextCure” or the “Company”) (NASDAQ: NXTC). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether NextCure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 



[Click here for information about joining the class action]

On January 13, 2020, NextCure disclosed in a U.S. Securities and Exchange Commission filing that Eli Lilly and Company had ended its 2018 research and development collaboration agreement with NextCure. 

On this news, NextCure’s stock price fell $4.70 per share, or 8.29%, to close at $52.00 per share on January 13, 2020. 

Then, on July 13, 2020, NextCure issued a press release announcing that the Company no longer planned to “advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial” for its NC318 immunomedicine product, citing “clinical response data” and “current enrollment criteria.”  NextCure concurrently announced the resignation of Kevin N. Heller from his role as the Company’s Chief Medical Officer. 

On this news, NextCure’s stock price fell $9.73 per share, or more than 54%, to close at $8.15 per share on July 13, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

New AMA PSA Urges Three Key Actions as COVID-19 Cases Spike

Wash your hands, practice physical distancing, and #MaskUp

Chicago, Nov. 11, 2020 (GLOBE NEWSWIRE) — With record numbers of COVID-19 cases and deaths being reported across the country, the American Medical Association (AMA) today released a public service announcement (PSA) urging the general public to take three simple steps to help stop the spread of COVID-19: wash your hands frequently, practice physical distancing by staying at least six feet away from others and #MaskUp. The PSA is part of ongoing efforts by America’s physicians to urge individuals to take the necessary health and safety precautions this season to protect themselves, loved ones and the healthcare workers who are on the front lines handling the dramatic increase in cases.

“As we enter a third wave of a pandemic that is causing increased illness and deaths across our country, we implore everyone to follow these three-simple science- and evidence-based steps to help stop the spread of COVID-19: wash your hands, practice physical distancing and wear a mask,” said AMA President Susan R. Bailey, M.D. “Cases are at record highs across the country, and with the holidays quickly approaching, each of us must do everything possible to reduce the spread of COVID-19. Failing to do our part will prolong the suffering and disruption to our lives, and inevitably lead to more deaths of our friends, neighbors and loved ones.”

Physicians are particularly concerned by the latest spike in cases, especially as it coincides with the start of flu season. Over the past week, there have been more than 100,000 new COVID-19 cases per day. The significant increase in new cases worsens shortages of personal protective equipment (PPE), tests and testing supplies and further stretches hospitals’ intensive care unit (ICU) capacity in many states.

The national PSA deployed by the AMA is part of its ongoing effort to encourage the American people to take concrete steps to stop the spread of COVID-19. To find out more about the work of the AMA around COVID-19 and resources it is providing to physicians and patients visit: https://www.ama-assn.org/topics/coronavirus-covid-19.

AMA Media & Editorial
American Medical Association 
312-464-4430
[email protected]

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Celsion Corporation of Class Action Lawsuit and Upcoming Deadline – CLSN

NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN). The class action, filed in United States District Court for the District of New Jersey, and docketed under 20-cv-015228, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Celsion securities between November 2, 2015 and July 10, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Celsion securities during the class period, you have until December 28, 2020, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 



[Click here for information about joining the class action]

Celsion is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer.

Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.

In February 2014, Celsion announced that the U.S. Food and Drug Administration (“FDA”) had reviewed and provided clearance for the Company’s planned pivotal, double-blind, placebo-controlled Phase III trial of ThermoDox in combination with radio frequency ablation (“RFA”) in primary liver cancer, also known as hepatocellular carcinoma (“HCC”), called the “OPTIMA Study.” The trial design was purportedly based on a comprehensive analysis of data from the Company’s Phase III HEAT Study, which purportedly demonstrated that treatment with ThermoDox resulted in a 55% improvement in overall survival (“OS”) in a substantial number of HCC patients that received an optimized RFA treatment.

The OPTIMA Study was expected to enroll 550 patients globally, with up to 100 sites in the U.S., Europe, China and Asia Pacific, to evaluate ThermoDox in combination with RFA. The primary endpoint for the trial was OS, and the statistical plan called for two interim efficacy analyses by an independent Data Monitoring Committee (“DMC”).

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations, and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants had significantly overstated the efficacy of ThermoDox; (ii) the foregoing significantly diminished the approval and commercialization prospects for ThermoDox; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 13, 2020, Celsion announced that “it ha[d] received a recommendation from the independent [DMC] to consider stopping the global Phase III OPTIMA Study of ThermoDox® in combination with [RFA] for the treatment of [HCC], or primary liver cancer.” According to the Company, “[t]he recommendation was made following the second pre-planned interim safety and efficacy analysis by the DMC on July 9, 2020,” which “found that the pre-specified boundary for stopping the trial for futility of 0.900 was crossed with an actual value of 0.903.”

On this news, Celsion’s stock price fell $2.29 per share, or 63.97%, to close at $1.29 per share on July 13, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980